Chemotherapy-Induced Cognitive Change and DNA Damage in Breast Cancer Survivors
The primary objective of this proposal is to obtain preliminary data regarding the
association between DNA damage and cognitive functioning in breast cancer survivors.
Specifically, we predict that:
1. Breast cancer survivors treated with chemotherapy and hormonal therapy will have higher
levels of DNA damage as measured by the Comet assay as compared to age and education
matched survivors treated with hormonal therapy only and healthy controls.
2. Survivors who meet criteria for cognitive impairment will have higher levels of DNA
damage as compared to cancer survivors who do not meet criteria for cognitive
impairment and healthy controls.
Observational Model: Cohort, Time Perspective: Retrospective
The primary goal of this preliminary study is to examine the relationship between DNA damage and chemotherapy-induced cognitive changes in breast cancer survivors.
conclusion of study
Tim Ahles, PhD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center at Commack||Commack, New York 11725|
|Memorial Sloan-Kettering Cancer Center at Mercy Medical Center||Rockville Centre, New York 11570|
|Memorial Sloan-Kettering Cancer Center 1275 York Avenue||New York, New York 10021|